New Analyst Rating price target $0.37 ...

The price target of 0.37 is wayyy to low we could hit this number on upcoming Partnerdeals which is imminent .This Stock is a great Investment with MEGA Upside Potential in the coming months. GL



http://imarketreports.com/drug-maker-idt-australia-just-the-tonic-for-morgans-market-talk.html


Drug Maker IDT Australia Just the Tonic for Morgans — Market Talk

0011 GMT [Dow Jones] Morgans starts pharmaceuticals company IDT Australia (IDT.AU) at add with a A$0.37/share price target, anticipating the business will increase revenue sharply in the second half of this fiscal year and swing to a profit in FY17. “Under new management IDT is shifting its focus from contract manufacture of pharmaceuticals to more in-house development,” analyst Scott Power says. IDT recently acquired a portfolio of 23 generic drugs, which Morgans thinks makes for a better strategy than supplying active pharmaceutical ingredients, or APIs. “We believe management’s decision to move further up the value chain and focus on finished products rather than primary API manufacturing will benefit the company in the medium/long term,” Power says. IDT last traded at A$0.17.